Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury

Journal of Neurotrauma

Volumn 32, Issue 5, 2015, Pages 297-306

  Katz, Paige S ^a   Sulzer, Jesse K ^a   Impastato, Renata A ^a   Teng, Sophie X ^a   Rogers, Emily K ^a   Molina, Patricia E ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 AG; AEA; endocannabinoids; neuroinflammation; TBI

Indexed keywords

2 ARACHIDONOYL GLYCEROL; 4 [BIS(1,3 BENZODIOXOL 5 YL)HYDROXYMETHYL] 1 PIPERIDINECARBOXYLIC ACID 4 NITROPHENYL ESTER; ANANDAMIDE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; CYCLOOXYGENASE 2; ENDOCANNABINOID; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; ARACHIDONIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; CARBAMIC ACID DERIVATIVE; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; N-ARACHIDONOYLETHANOLAMINE; NEUROPROTECTIVE AGENT; PIPERIDINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; APNEA; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CONTROLLED STUDY; CRANIOTOMY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RIGHTING REFLEX; TRAUMATIC BRAIN INJURY; WESTERN BLOTTING; ANIMAL; BRAIN INJURY; CONVALESCENCE; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ARACHIDONIC ACIDS; BENZAMIDES; BENZODIOXOLES; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BRAIN INJURIES; CARBAMATES; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; GLYCERIDES; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NEUROPROTECTIVE AGENTS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECOVERY OF FUNCTION;

EID: 84924151909     PISSN: 08977151     EISSN: 15579042     Source Type: Journal    
DOI: 10.1089/neu.2014.3508     Document Type: Article

References (64)

1. Warden, D. (2006). Military TBI during the Iraq and Afghanistan wars. J. Head Trauma Rehabil. 21, 398-402.
2. Terrio, H., Brenner, L.A., Ivins, B.J., Cho, J.M., Helmick, K., Schwab, K., Scally, K., Bretthauer, R., and Warden, D. (2009). Traumatic brain injury screening: preliminary findings in a US Army Brigade Combat Team. J. Head Trauma Rehabil. 24, 14-23.
3. Mayorga, M.A. (1997). The pathology of primary blast overpressure injury. Toxicology 121, 17-28.
4. McKee, A.C., Cantu, R.C., Nowinski, C.J., Hedley-Whyte, E., Gavett, B.E., Budson, A.E., Santini, V.E., Lee, H.S., Kubilus, C.A., and Stern, R.A. (2009). PMC2945234; chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J. Neuropathol. Exp. Neurol. 68, 709-735.
5. Faul, M., Xu, L., Wald, M.M., and Coronado, V.G. (2010). Traumatic brain injury in the United States: emergency department visits, hospitalizations and deaths, 2002-2006. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control: Atlanta, GA.
6. Elder, G.A., and Cristian, A. (2009). Blast-related mild traumatic brain injury: mechanisms of injury and impact on clinical care. Mt. Sinai J. Med. 76, 111-118.
7. Okie, S. (2005). Traumatic brain injury in the war zone. N. Engl. J. Med. 352, 2043-2047.
8. Riggio, S. (2011). Traumatic brain injury and its neurobehavioral sequelae. Neurol. Clin. 29, 35-47, vii.
9. Lenzlinger, P.M., Morganti-Kossmann, M., Laurer, H.L., and McIntosh, T.K. (2001). The duality of the inflammatory response to traumatic brain injury. Mol. Neurobiol. 24, 169-181.
10. Werner, C., and Engelhard, K. (2007). Pathophysiology of traumatic brain injury. Br. J. Anaesth. 99, 4-9.
11. Schmidt, O.I., Heyde, C.E., Ertel, W., and Stahel, P.F. (2005). Closed head injury-an inflammatory disease? Brain Res. Brain Res. Rev. 48, 388-399.
12. Chen, Y., Constantini, S., Trembovler, V., Weinstock, M., and Shohami, E. (1996). An experimental model of closed head injury in mice: pathophysiology, histopathology, and cognitive deficits. J. Neurotrauma 13, 557-568.
13. Lloyd, E., Somera-Molina, K., Van Eldik, L.J., Watterson, D.M., and Wainwright, M.S. (2008). PMC2483713; suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. J. Neuroinflammation 5, 28.
14. Jain, K.K. (2008). Neuroprotection in traumatic brain injury. Drug Discov. Today 13, 1082-1089.
15. Loane, D.J., and Faden, A.I. (2010). Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol. Sci. 31, 596-604.
16. Cernak, I., and Noble-Haeusslein, L.J. (2010). Traumatic brain injury: an overview of pathobiology with emphasis on military populations. J. Cereb. Blood Flow Metab. 30, 255-266.
17. Pitkänen, A., Longhi, L., Marklund, N., Morales, D.M., and McIntosh, T.K. (2005). Neurodegeneration and neuroprotective strategies after traumatic brain injury. Drug Discov. Today Dis. Mech. 2, 409-418.
18. Di Marzo, V., Bifulco, M., and De Petrocellis, L. (2004). The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3, 771-784.
19. Mackie, K., and Stella, N. (2006). Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J. 8, E298-E306.
20. Mechoulam, R., Panikashvili, D., and Shohami, E. (2002). Cannabinoids and brain injury: therapeutic implications. Trends Mol. Med. 8, 58-61.
21. Panikashvili, D., Shein, N.A., Mechoulam, R., Trembovler, V., Kohen, R., Alexandrovich, A., and Shohami, E. (2006). The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol. Dis. 22, 257-264.
22. Wilson, R.I., and Nicoll, R.A. (2002). Endocannabinoid signaling in the brain. Science 296, 678-682.
23. Savinainen, J.R., Jarvinen, T., Laine, K., and Laitinen, J.T. (2001). Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes. Br. J. Pharmacol. 134, 664-672.
24. Hwang, J., Adamson, C., Butler, D., Janero, D.R., Makriyannis, A., and Bahr, B.A. (2010). Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sci. 86, 615-623.
25. Yu, M., Ives, D., and Ramesha, C.S. (1997). Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J. Biol. Chem. 272, 21181-21186.
26. Kozak, K.R., Rowlinson, S.W., and Marnett, L.J. (2000). Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J. Biol. Chem. 275, 33744-33749.
27. Kozak, K.R., Prusakiewicz, J.J., and Marnett, L.J. (2004). Oxidative metabolism of endocannabinoids by COX-2. Curr. Pharm. Des. 10, 659-667.
28. Nadler, V., Biegon, A., Beit-Yannai, E., Adamchik, J., and Shohami, E. (1995). 45Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211. Brain Res. 685, 1-11.
29. Mauler, F., Horvath, E., De Vry, J., Jager, R., Schwarz, T., Sandmann, S., Weinz, C., Heinig, R., and Bottcher, M. (2003). BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Rev. 9, 343-358.
30. Biegon, A. (2004). Cannabinoids as neuroprotective agents in traumatic brain injury. Curr. Pharm. Des. 10, 2177-2183.
31. Tchantchou, F., and Zhang, Y. (2013). Selective inhibition of alpha/beta-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown and improves functional recovery in a mouse model of traumatic brain injury. J. Neurotrauma 30, 565-579.
32. Knoller, N., Levi, L., Shoshan, I., Reichenthal, E., Razon, N., Rappaport, Z.H., and Biegon, A. (2002). Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit. Care Med. 30, 548-554.
33. Shohami, E., Cohen-Yeshurun, A., Magid, L., Algali, M., and Mechoulam, R. (2011). Endocannabinoids and traumatic brain injury. Br. J. Pharmacol. 163, 1402-1410.
34. Correa, F., Mestre, L., Molina-Holgado, E., Arevalo-Martin, A., Docagne, F., Romero, E., Molina-Holgado, F., Borrell, J., and Guaza, C. (2005). The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation. Mini Rev. Med. Chem. 5, 671-675.
35. Downer, E.J. (2011). Cannabinoids and innate immunity: taking a toll on neuroinflammation. ScientificWorldJournal 11, 855-865.
36. Dixon, C.E., Lyeth, B.G., Povlishock, J.T., Findling, R.L., Hamm, R.J., Marmarou, A., Young, H.F., and Hayes, R.L. (1987). A fluid percussion model of experimental brain injury in the rat. J. Neurosurg. 67, 110-119.
37. McIntosh, T.K., Vink, R., Noble, L., Yamakami, I., Fernyak, S., Soares, H., and Faden, A.L. (1989). Traumatic brain injury in the rat: characterization of a lateral fluid-percussion model. Neuroscience 28, 233-244.
38. Thompson, H.J., Lifshitz, J., Marklund, N., Grady, M.S., Graham, D.I., Hovda, D.A., and McIntosh, T.K. (2005). Lateral fluid percussion brain injury: a 15-year review and evaluation. J. Neurotrauma 22, 42-75.
39. Ling, G.S.F., Lee, E.Y., and Kalehua, A.N. (2004). Traumatic brain injury in the rat using the fluid-percussion model. Curr. Protoc. Neurosci. Chapter 9, Unit 9.2.
40. Teng, S.X., and Molina, P.E. (2014). Acute alcohol intoxication prolongs neuroinflammation without exacerbating neurobehavioral dysfunction following mild traumatic brain injury. J. Neurotrauma 31, 378-386.
41. Boyko, M., Ohayon, S., Goldsmith, T., Novack, L., Novack, V., Perry, Z.H., Gruenbaum, B.F., Gruenbaum, S.E., Steiner, O., Shapira, Y., Teichberg, V.I., and Zlotnik, A. (2011). Morphological and neurobehavioral parallels in the rat model of stroke. Behav. Brain Res. 223, 17-23.
42. Euser, A.G., Bullinger, L., and Cipolla, M.J. (2008). Magnesium sulphate treatment decreases blood-brain barrier permeability during acute hypertension in pregnant rats. Exp. Physiol. 93, 254-261.
43. Xu, Q., Qaum, T., and Adamis, A.P. (2001). Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest. Ophthalmol. Vis. Sci. 42, 789-794.
44. de Jonge, H.J., Fehrmann, R.S., de Bont, E.S., Hofstra, R.M., Gerbens, F., Kamps, W.A., de Vries, E.G., van der Zee, A.G., te Meerman, G.J., and ter Elst, A. (2007). Evidence based selection of housekeeping genes. PLoS One 2, e898.
45. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanus, L., Breuer, A., Mechoulam, R., and Shohami, E. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527-531.
46. Maas, A.I., Murray, G., Henney, H., Kassem, N., Legrand, V., Mangelus, M., Muizelaar, J., Stocchetti, N., and Knoller, N. (2006). Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 5, 38-45.
47. Cravatt, B.F., Demarest, K., Patricelli, M.P., Bracey, M.H., Giang, D.K., Martin, B.R., and Lichtman, A.H. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U. S. A. 98, 9371-9376.
48. Nagayama, T., Sinor, A.D., Simon, R.P., Chen, J., Graham, S.H., Jin, K., and Greenberg, D.A. (1999). Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19, 2987-2995.
49. Povlishock, J.T. (1992). Traumatically induced axonal injury: pathogenesis and pathobiological implications. Brain Pathol. 2, 1-12.
50. Lloyd, E., Somera-Molina, K., Van Eldik, L.J., Watterson, D.M., and Wainwright, M.S. (2008). Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. J. Neuroinflammation 5, 28.
51. Lewen, A., Matz, P., and Chan, P.H. (2000). Free radical pathways in CNS injury. J. Neurotrauma 17, 871-890.
52. Tyurin, V.A., Tyurina, Y.Y., Borisenko, G.G., Sokolova, T.V., Ritov, V.B., Quinn, P.J., Rose, M., Kochanek, P., Graham, S.H., and Kagan, V.E. (2000). Oxidative stress following traumatic brain injury in rats: quantitation of biomarkers and detection of free radical intermediates. J. Neurochem. 75, 2178-2189.
53. Pratico, D., Reiss, P., Tang, L.X., Sung, S., Rokach, J., and McIntosh, T.K. (2002). Local and systemic increase in lipid peroxidation after moderate experimental traumatic brain injury. J. Neurochem. 80, 894-898.
54. Dubois, R.N., Abramson, S.B., Crofford, L., Gupta, R.A., Simon, L.S., Van De Putte, L.B., and Lipsky, P.E. (1998). Cyclooxygenase in biology and disease. FASEB J. 12, 1063-1073.
55. Strauss, K.I., Barbe, M.F., Marshall, R.M., Raghupathi, R., Mehta, S., and Narayan, R.K. (2000). Prolonged cyclooxygenase-2 induction in neurons and glia following traumatic brain injury in the rat. J. Neurotrauma 17, 695-711.
56. Gopez, J.J., Yue, H., Vasudevan, R., Malik, A.S., Fogelsanger, L.N., Lewis, S., Panikashvili, D., Shohami, E., Jansen, S.A., Narayan, R.K., and Strauss, K.I. (2005). Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. Neurosurgery 56, 590-604.
57. Wang, Z., Wei, X., Liu, K., Zhang, X., Yang, F., Zhang, H., He, Y., Zhu, T., Li, F., Shi, W., Zhang, Y., Xu, H., Liu, J., and Yi, F. (2013). NOX2 deficiency ameliorates cerebral injury through reduction of complexin II-mediated glutamate excitotoxicity in experimental stroke. Free Radic. Biol. Med. 65, 942-951.
58. Dohi, K., Ohtaki, H., Nakamachi, T., Yofu, S., Satoh, K., Miyamoto, K., Song, D., Tsunawaki, S., Shioda, S., and Aruga, T. (2010). Gp91phox (NOX2) in classically activated microglia exacerbates traumatic brain injury. J. Neuroinflammation 7, 41.
59. Ridet, J.L., Malhotra, S.K., Privat, A., and Gage, F.H. (1997). Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 20, 570-577.
60. Pekny, M., and Nilsson, M. (2005). Astrocyte activation and reactive gliosis. Glia 50, 427-434.
61. Eng, L.F., Ghirnikar, R.S., and Lee, Y.L. (2000). Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem. Res. 25, 1439-1451.
62. Stella, N. (2009). Endocannabinoid signaling in microglial cells. Neuropharmacology 56, Suppl 1, 244-253.
63. Stella, N. (2010). Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58, 1017-1030.
64. Weiss, J.M., Downie, S.A., Lyman, W.D., and Berman, J.W. (1998). Astrocyte-derived monocyte-chemoattractant protein-1 directs the transmigration of leukocytes across a model of the human blood-brain barrier. J. Immunol. 161, 6896-6903.